# IOVA catalysts: IOVANCE BIOTHERAPEUTICS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/iova/catalysts

> IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has 7 upcoming catalysts. The next is the Amtagvi® (lifileucel) interim data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | IOVANCE BIOTHERAPEUTICS, INC. |
| Ticker | IOVA (Nasdaq) |
| SEC CIK | 1425205 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/iova |

## Cash runway

Cash $376.3M as of 2026-09-30; quarterly burn $4.5M; about 252.6 months of runway at that rate (XBRL company facts, accession 0001193125-26-448809).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2023 | [Amtagvi® (lifileucel) NDA/BLA acceptance](https://sec-api.dev/pdufa/lifileucel) | IOVA |  | completed | "The FDA accepted our BLA for Amtagvi® for patients with advanced melanoma in May 2023 and granted lifileucel Priority Review." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1425205/000110465925107470/iova-20250930x10q.htm)) |
| February 16, 2024 | [Amtagvi® (lifileucel) FDA approval](https://sec-api.dev/pdufa/lifileucel) | IOVA | with post-anti-PD-1 advanced melanoma | completed, approved | "The U.S. FDA approved Amtagvi (lifileucel) on February 16, 2024, as the first treatment option for patients with advanced (unresectable or metastatic) melanoma after anti-PD-1 and targeted therapy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465925075175/tm2522769d1_ex99-1.htm)) |
| February 24, 2024 | [Amtagvi® (lifileucel) PDUFA date](https://sec-api.dev/pdufa/lifileucel) | IOVA |  | completed, approved | "The FDA originally assigned November 25, 2023 as the target action date for a decision under PDUFA, however, the FDA then reassigned February 24, 2024 as the revised target action date before approving the BLA on February 16, 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1425205/000155837025010807/iova-20250630x10q.htm)) |
| February 27, 2025 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465925018212/tm257755d1_ex99-1.htm)) |
| May 8, 2025 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465925046101/tm2514273d1_ex99-1.htm)) |
| August 7, 2025 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465925075175/tm2522769d1_ex99-1.htm)) |
| August 22, 2025 | [LN-145 primary completion](https://sec-api.dev/pdufa/ln-145) | IOVA | Cervical Carcinoma | withdrawn | "NCT03108495 (Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-08-22 (ACTUAL); Lead Sponsor Iovance Biotherapeutics, Inc.; Results First Posted 2026-07-31." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03108495)) |
| November 6, 2025 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "-- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported third quarter and year-to-date 2025 financial results, business achievements, pipeline progress, and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465925107426/tm2530236d1_ex99-1.htm)) |
| Feb 2026 | [Amtagvi® (lifileucel) interim data readout](https://sec-api.dev/pdufa/lifileucel) | IOVA | advanced UPS or DDLPS | completed, positive | "For example, in February 2026, we announced positive initial data from a pilot clinical trial led by MSKCC and supported by us of lifileucel in patients with advanced UPS or DDLPS who were refractory to at least one prior line of systemic therapy." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1425205/000119312526448809/iova-20260930.htm)) |
| February 20, 2026 | [LN-145 primary completion](https://sec-api.dev/pdufa/ln-145) | IOVA |  | withdrawn | "NCT03645928 (Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-02-20 (ACTUAL); Lead Sponsor Iovance Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03645928)) |
| February 24, 2026 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported fourth quarter and full year 2025 financial results, business achievements and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465926018837/tm266992d1_ex99-1.htm)) |
| Q2 2026 | [Amtagvi® (lifileucel) trial start](https://sec-api.dev/pdufa/lifileucel) | IOVA |  | scheduled | "We are conducting registrational trials for advanced NSCLC and frontline advanced melanoma cancer with our lifileucel product candidate, and we plan to commence a registrational trial in previously treated advanced UPS and DDLPS in the second quarter of 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1425205/000110465926056778/iova-20260331x10q.htm)) |
| May 7, 2026 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "(NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2026 financial results, business achievements, and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/tm2613648d1_ex99-1.htm)) |
| August 6, 2026 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "CARLOS, Calif., August 6, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter 2026 financial results, business achievements, and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/tm2622322d1_ex99-1.htm)) |
| November 5, 2026 | [IOVANCE BIOTHERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/iova/catalysts) | IOVA |  | completed | "Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported third quarter 2026 financial results, business achievements, and corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465926123030/tm2628901d1_ex99-1.htm)) |
| 1H 2027 | [Amtagvi® (lifileucel) interim data readout](https://sec-api.dev/pdufa/lifileucel) | IOVA |  | scheduled | "Multiple patients have been treated for cutaneous squamous cell carcinoma (CSCC) and Merkel cell carcinoma (MCC) with initial data expected in 1H27." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/tm2622322d1_ex99-1.htm)) |
| December 2027 | [Amtagvi® (lifileucel) primary completion](https://sec-api.dev/pdufa/lifileucel) | IOVA | Melanoma (Skin Cancer); Unresectable Melanoma; Metastatic Melanoma | scheduled | "NCT07288203 (A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Iovance Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288203)) |
| Dec 2027 to Mar 2028 | [Amtagvi® (lifileucel) topline data readout](https://sec-api.dev/pdufa/lifileucel) | IOVA | Melanoma (Skin Cancer); Unresectable Melanoma; Metastatic Melanoma | scheduled | "NCT07288203 (A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Iovance Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07288203)) |
| March 2028 | [Lifileucel plus pembrolizumab primary completion](https://sec-api.dev/pdufa/lifileucel-plus-pembrolizumab) | IOVA | Metastatic Melanoma; Unresectable Melanoma; Melanoma | scheduled | "NCT05727904 (Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-01 (ESTIMATED); Lead Sponsor Iovance Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05727904)) |
| Mar to Jun 2028 | [Lifileucel plus pembrolizumab topline data readout](https://sec-api.dev/pdufa/lifileucel-plus-pembrolizumab) | IOVA | Metastatic Melanoma; Unresectable Melanoma; Melanoma | scheduled | "NCT05727904 (Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-01 (ESTIMATED); Lead Sponsor Iovance Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05727904)) |
| May 2028 | [Amtagvi® (lifileucel) primary completion](https://sec-api.dev/pdufa/lifileucel) | IOVA | Endometrial Cancer | scheduled | "NCT06481592 (A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Iovance Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06481592)) |
| May to Aug 2028 | [Amtagvi® (lifileucel) topline data readout](https://sec-api.dev/pdufa/lifileucel) | IOVA | Endometrial Cancer | scheduled | "NCT06481592 (A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor Iovance Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06481592)) |

## Drugs

- [Amtagvi® (lifileucel)](https://sec-api.dev/pdufa/lifileucel): with post-anti-pd-1 advanced melanoma, advanced ups or ddlps, advanced melanoma, advanced, Endometrial Cancer, Melanoma (Skin Cancer)
- [Lifileucel plus pembrolizumab](https://sec-api.dev/pdufa/lifileucel-plus-pembrolizumab): Metastatic Melanoma
- [LN-145](https://sec-api.dev/pdufa/ln-145): Cervical Carcinoma, Metastatic Melanoma

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/iova/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "IOVA catalysts: IOVANCE BIOTHERAPEUTICS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/iova/catalysts

```bibtex
@misc{secapidev_companies_iova_catalysts_20261116,
  title        = {IOVA catalysts: IOVANCE BIOTHERAPEUTICS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/iova/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_iova_catalysts_20261116","title":"IOVA catalysts: IOVANCE BIOTHERAPEUTICS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/iova/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
